The 2009 study by Hussain et al. showed that a PSA-based intermediate end point might be useful in clinical trials of advanced prostate cancer. However, overall survival (OS) will remain the required end point of phase III studies and the search for a true, robust surrogate of OS to accelerate drug development continues.
- Gerhardt Attard
- Johann S. de Bono